Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corneel Coens

Showing results (41-50 of 125) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastomaTerri S Armstrong, Jeffrey S Wefel, Meihua Wang, et al.
The Lancet. Oncology|July 12, 2016
Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trialsIrina Ghislain, Efstathios Zikos, Corneel Coens, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 15, 2014
Joint modeling of longitudinal health-related quality of life data and survivalDivine E Ediebah, Francisca Galindo-Garre, Bernard M J Uitdehaag, et al.
Gynecologic Oncology|September 25, 2020
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancerJammbe Z Musoro, Corneel Coens, Elfriede Greimel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2023
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical TrialsBellinda L King-Kallimanis, Melanie Calvert, David Cella, et al.
BMJ Open|January 13, 2018
Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocolZebedee Jammbe Musoro, Jean-Francois Hamel, Divine Ewane Ediebah, et al.
Cancer|January 24, 2014
An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology GroupAndrew Bottomley, Gloria Tridello, Corneel Coens, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Reference values for the EORTC QLQ-C30 in early and metastatic breast cancerJustyna Mierzynska, Mekdes Taye, Madeline Pe, et al.
International Journal of Radiation Oncology, Biology, Physics|February 5, 2019
Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033Linda Dirven, Jaap C Reijneveld, Martin J B Taphoorn, et al.
Targeted Oncology|May 26, 2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyEvelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Pageof 13

Showing results (41-50 of 125) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastomaTerri S Armstrong, Jeffrey S Wefel, Meihua Wang, et al.
The Lancet. Oncology|July 12, 2016
Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trialsIrina Ghislain, Efstathios Zikos, Corneel Coens, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 15, 2014
Joint modeling of longitudinal health-related quality of life data and survivalDivine E Ediebah, Francisca Galindo-Garre, Bernard M J Uitdehaag, et al.
Gynecologic Oncology|September 25, 2020
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancerJammbe Z Musoro, Corneel Coens, Elfriede Greimel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 8, 2023
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical TrialsBellinda L King-Kallimanis, Melanie Calvert, David Cella, et al.
BMJ Open|January 13, 2018
Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocolZebedee Jammbe Musoro, Jean-Francois Hamel, Divine Ewane Ediebah, et al.
Cancer|January 24, 2014
An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology GroupAndrew Bottomley, Gloria Tridello, Corneel Coens, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Reference values for the EORTC QLQ-C30 in early and metastatic breast cancerJustyna Mierzynska, Mekdes Taye, Madeline Pe, et al.
International Journal of Radiation Oncology, Biology, Physics|February 5, 2019
Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033Linda Dirven, Jaap C Reijneveld, Martin J B Taphoorn, et al.
Targeted Oncology|May 26, 2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyEvelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Pageof 13